Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunder Biomedical Tech CoROCO:4115 -5.08%58 EV-to-EBITDA is 6.89 as of Sep. 04, 2026, which is 34% below its 10-year median of 10.37. GuruFocus rates ROCO:4115 with a GF Score™ of 58/100 and a GF Value™ of NT$9.37 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Sunder Biomedical Tech Co ranks better than 79.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sunder Biomedical Tech Co's enterprise value is NT$702.7 Mil.
Sunder Biomedical Tech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$102.0 Mil. Therefore, Sunder Biomedical Tech Co's EV-to-EBITDA for today is 6.89.
The historical rank and industry rank for Sunder Biomedical Tech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:4115'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.79 Med: 10.37 Max: 16.06
Current: 6.89
During the past 8 years, the highest EV-to-EBITDA of Sunder Biomedical Tech Co was 16.06. The lowest was 5.79. And the median was 10.37.
ROCO:4115's EV-to-EBITDA is ranked better than 79.22% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.26
vs ROCO:4115: 6.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sunder Biomedical Tech Co (ROCO:4115) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunder Biomedical Tech Co's PE Ratio (TTM) for today is calculated as:
Sunder Biomedical Tech Co's share price for today is NT$6.92.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunder Biomedical Tech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4115 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Sunder Biomedical Tech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunder Biomedical Tech Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sunder Biomedical Tech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sunder Biomedical Tech Co's EV-to-EBITDA falls into.
Sunder Biomedical Tech Co's current Enterprise Value is NT$702.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunder Biomedical Tech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$102.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunder Biomedical Tech Co (ROCO:4115) has a EV-to-EBITDA of 6.89 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunder Biomedical Tech Co. This is 34% below median its historical median of 10.37. Over the past decade, Sunder Biomedical Tech Co's EV-to-EBITDA has ranged from 5.79 to 16.06. According to the industry distribution chart, Sunder Biomedical Tech Co ranks #107 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Sunder Biomedical Tech Co's EV-to-EBITDA too high?
Sunder Biomedical Tech Co's current EV-to-EBITDA of 6.89 is 34% below median its 10-year median of 10.37. Over the past 10 years, this metric has ranged from a low of 5.79 to a high of 16.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.26. Sunder Biomedical Tech Co's value of 6.89 is 51.7% below this industry median. Based on the distribution chart, Sunder Biomedical Tech Co ranks #107 out of 515 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sunder Biomedical Tech Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunder Biomedical Tech Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sunder Biomedical Tech Co ranks #107 out of 515 companies for EV-to-EBITDA. This places Sunder Biomedical Tech Co in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.26. Sunder Biomedical Tech Co's value of 6.89 is 51.7% below this benchmark. Historically, Sunder Biomedical Tech Co's own EV-to-EBITDA has ranged from 5.79 to 16.06 over the past decade. While the company's 10-year median is 10.37 vs. the industry median of 14.26, Sunder Biomedical Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.26, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunder Biomedical Tech Co's current EV-to-EBITDA of 6.89 is 51.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sunder Biomedical Tech Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunder Biomedical Tech Co's current EV-to-EBITDA is 6.89, which is 34% below median its own 10-year median of 10.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunder Biomedical Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co (ROCO:4115) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$9.37, compared to a current price of NT$6.92 — trading 26.1% below its estimated fair value. The current EV-to-EBITDA is 6.89, which is 34% below median its 10-year median of 10.37 and 51.7% below the Medical Devices & Instruments industry median of 14.26. Sunder Biomedical Tech Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sunder Biomedical Tech Co (ROCO:4115), the current EV-to-EBITDA is 6.89 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunder Biomedical Tech Co (ROCO:4115) Overvalued in 2026?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co stock appears to be undervalued.
The current stock price of NT$6.92 is trading 26.1% below its estimated GF Value™ of NT$9.37.
GuruFocus considers Sunder Biomedical Tech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4115:
EV-to-EBITDA: 6.89 (34% below median its 10-year median of 10.37)
GF Value™: NT$9.37 vs. price of NT$6.92 (26.1% below fair value)
Industry Position: 51.7% below the Medical Devices & Instruments median (#107 of 515)
No single metric tells the full story. See the ROCO:4115 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.
58GF Score
Get the complete analysis for ROCO:4115
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4115 has been successfully added to your 
